Inferra AI / Company / MLYS
Mineralys Therapeutics, Inc.
MLYS · Health Care
Last earnings Aug 11, 2026
AI analysis
Q2 2025 · reported Aug 12, 2025
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
The event-summary record for this company carries no extracted figures, so the brief and charts cannot be drawn yet. The summary below and the held documents are the record for this event.
Guidance · company-stated
No guidance located in the held release
Capital allocation
Since inception, the Company has funded its operations by raising aggregate gross proceeds of approximately $ 1.4 billion from sales of common stock, convertible preferred stock, pre-funded warrants, and convertible notes, as well as borrowings under the Loan Agreement (as defined and further described in Note 6, Senior Secured Term Loan ).
Event summary
In the first half of 2025, we announced positive results from three clinical trials evaluating lorundrostat for the treatment of participants with uncontrolled or resistant hypertension
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Guidance & outlook
No guidance located in the held release
Capital allocation
Since inception, the Company has funded its operations by raising aggregate gross proceeds of approximately $ 1.4 billion from sales of common stock, convertible preferred stock, pre-funded warrants, and convertible notes, as well as borrowings under the Loan Agreement (as defined and further described in Note 6, Senior Secured Term Loan ).
SEC original ↗Mineralys Therapeutics, Inc. — 10-Q Quarterly report10-QAug 11, 2026
The Company expects to finance its operations through equity offerings, debt financings, and other capital sources, including potential strategic collaborations, licensing, and other similar arrangements.
SEC original ↗Mineralys Therapeutics, Inc. — 10-Q Quarterly report10-QAug 11, 2026
Investments The Company generally invests its excess cash in money market funds and investment-grade short- and long-term fixed-income debt securities, such as U.
SEC original ↗Mineralys Therapeutics, Inc. — 10-Q Quarterly report10-QAug 11, 2026
Notes to Condensed Financial Statements (unaudited) Debt Discounts, Debt Premiums, and Debt Issuance Costs The Company records debt obligations at their outstanding principal amount, adjusted for any unamortized debt discounts, debt premiums, and debt issuance costs.
SEC original ↗Mineralys Therapeutics, Inc. — 10-Q Quarterly report10-QAug 11, 2026
Debt discounts and debt issuance costs are presented as reductions of the carrying amount of the related debt liability while debt premiums are presented as increases to the carrying amount of the related debt liability.
SEC original ↗Mineralys Therapeutics, Inc. — 10-Q Quarterly report10-QAug 11, 2026
Debt discounts, debt premiums, and debt issuance costs allocated to drawn tranches are amortized to interest expense using the effective interest method over the contractual term of the related debt.
SEC original ↗Mineralys Therapeutics, Inc. — 10-Q Quarterly report10-QAug 11, 2026
Strategy & priorities
(Nasdaq MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced financial results for the second quarter ended June 30, 2025, and provided a corporate update.
SEC original ↗Mineralys Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 12, 2025
The results from our clinical program have positioned us to move ahead with our NDA strategy, and we have scheduled a pre-NDA meeting with the FDA to take place in the fourth quarter of 2025.
SEC original ↗Mineralys Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 12, 2025
About Mineralys Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as CKD, OSA and other diseases driven by dysregulated aldosterone.
SEC original ↗Mineralys Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 12, 2025
(the Company) is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone.
SEC original ↗Mineralys Therapeutics, Inc. — 10-Q Quarterly report10-QAug 11, 2026
The Company expects to finance its operations through equity offerings, debt financings, and other capital sources, including potential strategic collaborations, licensing, and other similar arrangements.
SEC original ↗Mineralys Therapeutics, Inc. — 10-Q Quarterly report10-QAug 11, 2026
Risks & headwinds
Legal Proceedings 33 Item 1A.
SEC original ↗Mineralys Therapeutics, Inc. — 10-Q Quarterly report10-QAug 11, 2026
Litigation Liabilities for loss contingencies arising from claims, assessments, litigation, fines, penalties, and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated.
SEC original ↗Mineralys Therapeutics, Inc. — 10-Q Quarterly report10-QAug 11, 2026
From time to time, the Company may become involved in legal proceedings arising in the ordinary course of business.
SEC original ↗Mineralys Therapeutics, Inc. — 10-Q Quarterly report10-QAug 11, 2026
The Company was not subject to any material legal proceedings during the three and six months ended June 30, 2026 and 2025, and no material legal proceedings are currently pending or threatened.
SEC original ↗Mineralys Therapeutics, Inc. — 10-Q Quarterly report10-QAug 11, 2026
These statements involve known and unknown risks, uncertainties, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements, including the timing, volume, and nature of feedback or requests from the FDA in connection with our NDA submission, macroeconomic trends and uncertainty with regard to high interest rates, elevated inflation, tariffs and other trade policies, geopolitical conflict, and the potential for a local and/or global economic recession.
SEC original ↗Mineralys Therapeutics, Inc. — 10-Q Quarterly report10-QAug 11, 2026
In addition, projections, assumptions, and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.
SEC original ↗Mineralys Therapeutics, Inc. — 10-Q Quarterly report10-QAug 11, 2026
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
34 documents- Q3 2026
- 8-KMLYS
- Q2 2026
- 8-KMLYS
- EX-99MLYS
- 10-QMLYS
- Q1 2026
- 8-KMLYS
- 8-KMLYS
- 8-KMLYS
- 8-KMLYS
- EX-99MLYS
- 10-QMLYS
- Q4 2025
- 8-KMLYS
- 10-KMLYS
- 8-KMLYS
- EX-99MLYS
- 8-KMLYS
- EX-99MLYS
- Q3 2025
- 8-KMLYS
- 10-QMLYS
- Q2 2025
- 8-KMLYS
- 8-KMLYS
- 8-KMLYS
- 10-QMLYS
- Q1 2025
- 8-KMLYS
- 8-KMLYS
- 8-KMLYS
- 10-QMLYS
- Q4 2024
- 8-KMLYS
- 8-KMLYS
- 8-KMLYS
- 8-KMLYS
- 10-KMLYS
- 8-KMLYS
- 8-KMLYS
- Q3 2024
- 10-QMLYS
Earnings releases
6 documentsPresentations
0 documentsNo presentations for Mineralys Therapeutics, Inc. are held in this edition of the library.
Transcripts
0 documentsNo transcripts for Mineralys Therapeutics, Inc. are held in this edition of the library.
See also the earnings calendar for every tracked company’s next earnings date.